Candel Therapeutics Inc Stock News

Candel Therapeutics Inc (NASDAQ:CADL) has provided a corporate update, highlighting anticipated milestones for this year building upon significant achievements in 2024.   Updated overall survival data from phase 2a trials of its lead candidate CAN-2409 in pancreatic ductal adenocarcinoma (PDAC) and non-small cell lung cancer (NSCLC) are expected in the first quarter of 2025.

NEEDHAM, Mass., Jan. 13, 2025 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical stage biopharmaceutical company focused on developing multimodal biological immunotherapies to help patients fight cancer, today highlighted recent successes across the Company's viral immunotherapy portfolio and provided an update on the Company's cash position and upc...

Taking a look at the 20 best-performing stocks in 2024 of current Russell 3,000 members.

In the New Year, many small-cap biotech companies will be advancing promising clinical trials with innovative therapies aimed at addressing significant unmet medical needs. Key trials include those focused on cancer immunotherapies, treatments for neurological conditions like multiple sclerosis and Alzheimer's, as well as novel approaches to metabolic diseases and chronic pain.

Candel Therapeutics Inc (NASDAQ:CADL) shares skyrocketed by nearly 43% on Thursday following a string of positive news surrounding the company's cancer drug pipeline. Last week the Needham, Massachusetts-based company released promising results from its Phase 3 clinical trial for CAN-2409, its experimental immunotherapy for localized prostate cancer.

Candel Therapeutics Inc (NASDAQ:CADL) announced on Monday the completion of a public offering that raised approximately $92 million in gross proceeds. The offering included 12 million shares of common stock at $6 per share and pre-funded warrants for 3.3 million shares at $5.99 per warrant, allowing buyers to acquire shares at an exercise price of $0.01 each.

NEEDHAM, Mass., Dec. 16, 2024 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (“Candel”) (Nasdaq: CADL), a clinical stage biopharmaceutical company focused on developing multimodal biological immunotherapies to help patients fight cancer, today announced the closing of its previously announced underwritten public offering of 12,000,001 shares of its common stock at a price to the public of $6.00 ...

Candel Therapeutics Inc (NASDAQ:CADL) has announced an $80 million underwritten public offering of its common stock and pre-funded warrants. The offering includes approximately 10 million shares of common stock at $6 per share and approximately 3.33 million pre-funded warrants priced at $5.99 each, representing the public offering price minus a $0.01 per share exercise cost.